Holen Sie sich die Stockscreener-App
10.13
6.38%
-0.69
Schlusskurs vom Vortag:
$10.82
Offen:
$10.87
24-Stunden-Volumen:
860.36K
Relative Volume:
0.82
Marktkapitalisierung:
$614.66M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-11.01
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
-3.34%
1M Leistung:
-18.90%
6M Leistung:
+102.20%
1J Leistung:
+211.69%
1-Tages-Spanne:
$10.12
$11.00
1-Wochen-Bereich:
$10.12
$11.28
52-Wochen-Spanne:
$3.03
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
10.13 | 614.66M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Analysts Provide An Important Insights On CorMedix Inc (CRMD) - Stocks Register
Elliott Investment Management Buys Wolfspeed Stock, Bets Against Nvidia In Q4 - Benzinga
CorMedix Inc. Announces Resignation of Member of Its Board of Directors - ACCESS Newswire
CorMedix's SWOT analysis: defencath launch propels stock, expansion plans eyed - Investing.com India
(CRMD) Investment Report - Stock Traders Daily
Top investors say CorMedix Inc (CRMD) ticks everything they need - SETE News
BlackRock, Inc. Increases Stake in Cormedix Inc. - GuruFocus.com
A stock that deserves closer examination: CorMedix Inc (CRMD) - US Post News
D. Boral Capital’s latest rating for CRMD stock - Knox Daily
Daily Progress: CorMedix Inc (CRMD) Drop -6.38, Closing at 10.27 - The Dwinnex
Where are the Opportunities in (CRMD) - Stock Traders Daily
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely - Yahoo Finance
CorMedix Inc. Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities - Marketscreener.com
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities - The Manila Times
CorMedix Partners with WSI PBG to Bring DefenCath to 40,000 Veterans with Kidney Disease - StockTitan
Trading (CRMD) With Integrated Risk Controls - Stock Traders Daily
CorMedix Partners With WSI PBG To Improve Access To DefenCath For ESRD Patients - Nasdaq
Boral Capital sets CorMedix stock target, Buy rating on potential By Investing.com - Investing.com Australia
Boral Capital sets CorMedix stock target, Buy rating on potential - Investing.com
I’m (Finally) a Believer in This Low-Priced Biotech - TheStreet
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates - MSN
CorMedix soars on Q4 preliminary results, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat - Investing.com India
CorMedix Soars 32% on Upbeat Q4 Forecast - Wall Street Pit
CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates - MarketWatch
CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) - Seeking Alpha
CorMedix soars on Q4 preliminary resyults, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat By Investing.com - Investing.com Canada
CRMDCorMedix Inc. Latest Stock News & Market Updates - StockTitan
CorMedix soars on Q4 preliminary results, business updates (CRMD:NASDAQ) - Seeking Alpha
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update - The Manila Times
CorMedix reports preliminary Q4 net revenue $31M - TipRanks
CorMedix Hits Breakeven Target with $31M Q4 Revenue, Secures $25M in New Orders for DefenCath - StockTitan
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year? - MSN
CorMedix price target raised to $12 from $11 at RBC Capital - Yahoo Finance
RBC optimistic on CorMedix shares as DefenCath launch gains traction in outpatient - Investing.com India
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans - Investing.com Australia
CorMedix Inc. Added to Nasdaq Biotechnology Index - The Manila Times
CorMedix joins Nasdaq Biotechnology Index - Investing.com
CorMedix joins Nasdaq Biotechnology Index By Investing.com - Investing.com UK
CorMedix (CRMD) Earns Coveted Spot in Nasdaq Biotechnology Index in December Update - StockTitan
Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Insider Monkey
CorMedix's SWOT analysis: defencath launch propels stock amid expansion By Investing.com - Investing.com Nigeria
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):